Mulling over the consequences of Centoxin II, we've stumbled into the long-running issue involving the divergence of shareholder and management priorities when it comes to managing risk.

BioCentury's cover story this week explores the strategies executives are using to hedge against disaster befalling their marquee program. Their message: shareholder value is enhanced by creating alternatives to a single bet-the-company project.